Skip to main content

Table 4 Frequency of reason for discontinuation of c-DMARD and b-DMARD by medication type

From: Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study

  c-DMARD b-DMARD
MTX SFZ Other c-DMARDa Total number ETN ADL Other b-DMARDb Total number
Remission 41 (40%) 9 (24%) 4 (20%) 54 (34%) 5 (15%) 1 (7%) 0 6 (9%)
Lack of effectiveness 9 (9%) 10 (27%) 4 (20%) 23 (14%) 18 (55%) 10 (67%) 13 (72%) 41 (62%)
Side effects 37 (36%) 11 (30%) 8 (40%) 56 (35%) 6 (18%) 3 (20%) 4 (22%) 13 (20%)
Adherence issue 10 (10%) 7 (19%) 1 (5%) 18 (10%) 4 (12%) 0 0 4 (6%)
Other reasons 0 0 1 (5%) 1 (1%) 0 1 (7%) 1 (6%) 2 (4%)
Reason not reported 5 (5%) 0 2 (10%) 7 (4%) 0 0 0 0
Total 102 37 20 159 33 15 18 66
  1. MTX Methotrexate, SFZ Sulfasalazine, ETN Etanercept, ADL Adalimumab, c-DMARD Conventional disease anti-rheumatic drugs, b-DMARD b-biologic disease anti-rheumatic drugs
  2. aOther c-DMARD include hydroxychloroquine and leflunomide
  3. bOther b-DMARD include certolizumab, golimumab, tocilizumab, infliximab, secukinumab, tofacitinib, and abatacept